Rifampin Capsules Recalled Due to Incomplete Stability Studies
Akorn, Inc. is recalling all lots of Rifampin Capsules USP 150 mg distributed nationwide due to manufacturing deviations. The company ceased business before completing required stability studies to verify the drug remains safe and effective throughout its shelf life.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall with CGMP deviations related to incomplete stability studies. No illnesses or injuries have been reported, but the incomplete stability data represents a risk-of-harm scenario where the drug's long-term safety and efficacy cannot be fully verified.
Plain-English summary
Akorn, Inc. is recalling all lots of Rifampin Capsules USP 150 mg, 30-count bottles (Rx only), distributed nationwide in the USA and Puerto Rico. The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations.
The company went out of business and could no longer continue or complete stability studies required by FDA regulations. Stability studies are critical to verify that a drug remains safe and effective throughout its approved shelf life. Without these studies, the FDA cannot confirm the product maintains its intended strength, quality, and purity.
Patients currently taking this medication should not stop their treatment without consulting their healthcare provider, as interrupting antibiotic therapy could be harmful. Patients should contact their pharmacist or healthcare provider to discuss alternative treatments or proper disposal of any remaining supply. Healthcare providers should review patient records for dispensing of this product and arrange suitable alternatives where needed.
The recalled product
- Product
- Rifampin Capsules USP, 150 mg, 30-count bottles, Rx Only, Sterile, Distributed by: Akorn Operating Company LLC, Gurnee, IL 60031. ALL NDCs
- Manufacturer
- Akorn, Inc.
- Category
- Drug
- Hazard
- cgmp-deviation
- stability-gap
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All Lots
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27